Biocytogen and Whitehawk Therapeutics are joining forces to develop bispecific antibody-drug conjugates (ADCs) using Biocytogen's proprietary discovery platform. Whitehawk will evaluate five Biocytogen-supplied bispecific antibodies and will have the option to advance any resulting ADC candidates as part of Whitehawk's pipeline. The deal includes an upfront and potential milestone payments coming ...